Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 6
1981 5
1982 5
1983 16
1984 21
1985 26
1986 27
1987 44
1988 49
1989 46
1990 49
1991 35
1992 34
1993 23
1994 30
1995 24
1996 33
1997 33
1998 33
1999 45
2000 29
2001 38
2002 40
2003 37
2004 30
2005 24
2006 21
2007 27
2008 15
2009 20
2010 19
2011 15
2012 10
2013 18
2014 19
2015 11
2016 16
2017 14
2018 15
2019 12
2020 23
2021 17
2022 16
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

1,038 results

Results by year

Filters applied: . Clear all
Page 1
Are there any benefits of Betoptic S (betaxolol HCl ophthalmic suspension) over other beta-blockers in the treatment of glaucoma?
Yarangümeli A, Kural G. Yarangümeli A, et al. Expert Opin Pharmacother. 2004 May;5(5):1071-81. doi: 10.1517/14656566.5.5.1071. Expert Opin Pharmacother. 2004. PMID: 15155109 Review.
The cardioselective beta-blocker, betaxolol, is an effective ocular antihypertensive agent. Its mode of action in lowering intraocular pressure is similar to that of the nonselective blockers, by suppressing the flow of aqueous humor. The most frequent adverse reaction to …
The cardioselective beta-blocker, betaxolol, is an effective ocular antihypertensive agent. Its mode of action in lowering intraocula …
Early Manifest Glaucoma Trial: design and baseline data.
Leske MC, Heijl A, Hyman L, Bengtsson B. Leske MC, et al. Ophthalmology. 1999 Nov;106(11):2144-53. doi: 10.1016/s0161-6420(99)90497-9. Ophthalmology. 1999. PMID: 10571351 Clinical Trial.
Treated patients had laser trabeculoplasty and started receiving topical betaxolol twice daily in eligible eyes. Follow-up visits include computerized perimetry and tonometry every 3 months and fundus photography every 6 months. ...
Treated patients had laser trabeculoplasty and started receiving topical betaxolol twice daily in eligible eyes. Follow-up visits inc …
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Heijl A, et al. Arch Ophthalmol. 2002 Oct;120(10):1268-79. doi: 10.1001/archopht.120.10.1268. Arch Ophthalmol. 2002. PMID: 12365904 Clinical Trial.
INTERVENTIONS: Patients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial treatment (n = 126). ...
INTERVENTIONS: Patients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial …
Betaxolol: A comprehensive profile.
Al-Wadei MJ, Bakheit AH, Abdel-Aziz AA, Wani TA. Al-Wadei MJ, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:91-136. doi: 10.1016/bs.podrm.2020.07.002. Epub 2020 Aug 21. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461701 Review.
Betaxolol selectively and competitively binds to and blocks beta-1 (beta1) adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. ...Betaxolol (S)-(-)-enantiomer shows higher pharmacological activity. ...
Betaxolol selectively and competitively binds to and blocks beta-1 (beta1) adrenergic receptors in the heart, thereby decreasing card …
Betaxolol.
Goldberg I. Goldberg I. Aust N Z J Ophthalmol. 1989 Feb;17(1):9-13. doi: 10.1111/j.1442-9071.1989.tb00483.x. Aust N Z J Ophthalmol. 1989. PMID: 2569884 Review.
Actual and potential side effects associated with its non-selective beta-blockade have prevented its use in patients with reactive airways disease, and to a lesser extent, with various cardiovascular conditions. Betaxolol is a relatively selective beta-1 blocker which in m …
Actual and potential side effects associated with its non-selective beta-blockade have prevented its use in patients with reactive airways d …
Wettability and contact angle affect precorneal retention and pharmacodynamic behavior of microspheres.
Liu H, Han X, Li H, Tao Q, Hu J, Liu S, Liu H, Zhou J, Li W, Yang F, Ping Q, Wei S, Liu H, Lin H, Hou D. Liu H, et al. Drug Deliv. 2021 Dec;28(1):2011-2023. doi: 10.1080/10717544.2021.1981493. Drug Deliv. 2021. PMID: 34569888 Free PMC article.
In the present study, we describe the development of betaxolol hydrochloride and montmorillonite with ion exchange in a single formulation to create a novel micro-interactive dual-functioning sustained-release delivery system (MIDFDS) for the treatment of glaucoma. Beta …
In the present study, we describe the development of betaxolol hydrochloride and montmorillonite with ion exchange in a single formul …
Betaxolol and timolol.
Harrison R. Harrison R. Arch Ophthalmol. 1984 Oct;102(10):1424, 1426. doi: 10.1001/archopht.1984.01040031154003. Arch Ophthalmol. 1984. PMID: 6148923 Clinical Trial. No abstract available.
Ion exchange resins for ophthalmic delivery.
Jani R, Gan O, Ali Y, Rodstrom R, Hancock S. Jani R, et al. J Ocul Pharmacol. 1994 Spring;10(1):57-67. doi: 10.1089/jop.1994.10.57. J Ocul Pharmacol. 1994. PMID: 8207345
This delivery system also optimized the bioavailability of Betaxolol, reducing the total drug concentration in half to 0.25% Betaxolol in 0.25% BETOPTIC S Ophthalmic Suspension as compared with 0.5% Betaxolol in BETOPTIC 0.5% Sterile Ophthalmic …
This delivery system also optimized the bioavailability of Betaxolol, reducing the total drug concentration in half to 0.25% Betax …
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H2S Donors.
Sparaco R, Citi V, Magli E, Martelli A, Piragine E, Calderone V, Andreozzi G, Perissutti E, Frecentese F, Santagada V, Caliendo G, Severino B, Corvino A, Fiorino F. Sparaco R, et al. Int J Mol Sci. 2022 Nov 9;23(22):13804. doi: 10.3390/ijms232213804. Int J Mol Sci. 2022. PMID: 36430281 Free PMC article.
In this work, we designed and synthetized new molecular hybrids between antiglaucoma drugs and H(2)S donors to combine the pharmacological effect of both moieties, providing a heightened therapy. Brinzolamide, betaxolol and brimonidine were linked to different H(2)S donors …
In this work, we designed and synthetized new molecular hybrids between antiglaucoma drugs and H(2)S donors to combine the pharmacological e …
1,038 results